Cargando…

Plasma Lipocalin-2 and Adiponectin are Affected by Obesity Rather Than Type 2 Diabetes Mellitus per se

PURPOSE: Changes in plasma adipocytokines and inflammatory markers in type 2 DM remain controversial as to whether they are due to obesity or directly associated with the diabetic state. Our objective was to study the effect of obesity and diabetes on plasma lipocalin-2 (LCN2), adiponectin, and inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Absi, Boshra, AL-Habori, Molham, Saif-Ali, Riyadh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605802/
https://www.ncbi.nlm.nih.gov/pubmed/34815681
http://dx.doi.org/10.2147/DMSO.S338254
_version_ 1784602230478864384
author Al-Absi, Boshra
AL-Habori, Molham
Saif-Ali, Riyadh
author_facet Al-Absi, Boshra
AL-Habori, Molham
Saif-Ali, Riyadh
author_sort Al-Absi, Boshra
collection PubMed
description PURPOSE: Changes in plasma adipocytokines and inflammatory markers in type 2 DM remain controversial as to whether they are due to obesity or directly associated with the diabetic state. Our objective was to study the effect of obesity and diabetes on plasma lipocalin-2 (LCN2), adiponectin, and interleukin-1β (IL-1β) by comparing their levels in non-diabetic obese subjects and non-obese type 2 DM patients, as well as determining the association of these adipocytokines with metabolic syndrome factors and diabetic parameters. PATIENTS AND METHODS: In this study, 85 Yemeni male volunteers aged 30–60 years old were enrolled, 25 of whom were healthy subjects with BMI < 25 kg/m(2) served as control; 30 non-diabetic obese subjects (BMI ≥ 30 kg/m(2) and FBG < 6.1 mmol/l); and 30 non-obese type 2 DM patients (BMI < 25 kg/m(2) and FBG > 7 mmol/l). RESULTS: Lipocalin-2 and adiponectin were significantly (p = 0.043 and p = 0.034) lower in non-diabetic obese subjects by 16.2% and 29.7% with respect to control group, with no effect in the non-obese type 2 DM patients. Moreover, LCN2 was significantly (p = 0.04) lower in the non-diabetic obese subjects by 15.8% as compared with the non-obese type 2 DM patients, with no significant difference in adiponectin levels. In contrast, serum IL-1β was significantly (p = 0.001 and p = 0.003) higher in both non-diabetic obese subjects and the non-obese type 2 DM patients by 76.5% and 67.7% as compared to control group. The significant decrease in both LCN2 and adiponectin and the significant increase in IL-1β in the non-diabetic obese subjects disappeared upon adjustment for waist circumference (WC). In contrast, the significant increase in IL-1β in the non-obese Type 2 DM patients was not affected upon adjustment for WC. CONCLUSION: Plasma LCN2 and adiponectin were not affected by diabetes per se, suggesting that the observed changes in LCN2 and adiponectin in type 2 DM may be due to obesity rather than the diabetic state, whereas IL-1β levels were affected by both obesity and diabetes.
format Online
Article
Text
id pubmed-8605802
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86058022021-11-22 Plasma Lipocalin-2 and Adiponectin are Affected by Obesity Rather Than Type 2 Diabetes Mellitus per se Al-Absi, Boshra AL-Habori, Molham Saif-Ali, Riyadh Diabetes Metab Syndr Obes Original Research PURPOSE: Changes in plasma adipocytokines and inflammatory markers in type 2 DM remain controversial as to whether they are due to obesity or directly associated with the diabetic state. Our objective was to study the effect of obesity and diabetes on plasma lipocalin-2 (LCN2), adiponectin, and interleukin-1β (IL-1β) by comparing their levels in non-diabetic obese subjects and non-obese type 2 DM patients, as well as determining the association of these adipocytokines with metabolic syndrome factors and diabetic parameters. PATIENTS AND METHODS: In this study, 85 Yemeni male volunteers aged 30–60 years old were enrolled, 25 of whom were healthy subjects with BMI < 25 kg/m(2) served as control; 30 non-diabetic obese subjects (BMI ≥ 30 kg/m(2) and FBG < 6.1 mmol/l); and 30 non-obese type 2 DM patients (BMI < 25 kg/m(2) and FBG > 7 mmol/l). RESULTS: Lipocalin-2 and adiponectin were significantly (p = 0.043 and p = 0.034) lower in non-diabetic obese subjects by 16.2% and 29.7% with respect to control group, with no effect in the non-obese type 2 DM patients. Moreover, LCN2 was significantly (p = 0.04) lower in the non-diabetic obese subjects by 15.8% as compared with the non-obese type 2 DM patients, with no significant difference in adiponectin levels. In contrast, serum IL-1β was significantly (p = 0.001 and p = 0.003) higher in both non-diabetic obese subjects and the non-obese type 2 DM patients by 76.5% and 67.7% as compared to control group. The significant decrease in both LCN2 and adiponectin and the significant increase in IL-1β in the non-diabetic obese subjects disappeared upon adjustment for waist circumference (WC). In contrast, the significant increase in IL-1β in the non-obese Type 2 DM patients was not affected upon adjustment for WC. CONCLUSION: Plasma LCN2 and adiponectin were not affected by diabetes per se, suggesting that the observed changes in LCN2 and adiponectin in type 2 DM may be due to obesity rather than the diabetic state, whereas IL-1β levels were affected by both obesity and diabetes. Dove 2021-11-16 /pmc/articles/PMC8605802/ /pubmed/34815681 http://dx.doi.org/10.2147/DMSO.S338254 Text en © 2021 Al-Absi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Al-Absi, Boshra
AL-Habori, Molham
Saif-Ali, Riyadh
Plasma Lipocalin-2 and Adiponectin are Affected by Obesity Rather Than Type 2 Diabetes Mellitus per se
title Plasma Lipocalin-2 and Adiponectin are Affected by Obesity Rather Than Type 2 Diabetes Mellitus per se
title_full Plasma Lipocalin-2 and Adiponectin are Affected by Obesity Rather Than Type 2 Diabetes Mellitus per se
title_fullStr Plasma Lipocalin-2 and Adiponectin are Affected by Obesity Rather Than Type 2 Diabetes Mellitus per se
title_full_unstemmed Plasma Lipocalin-2 and Adiponectin are Affected by Obesity Rather Than Type 2 Diabetes Mellitus per se
title_short Plasma Lipocalin-2 and Adiponectin are Affected by Obesity Rather Than Type 2 Diabetes Mellitus per se
title_sort plasma lipocalin-2 and adiponectin are affected by obesity rather than type 2 diabetes mellitus per se
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605802/
https://www.ncbi.nlm.nih.gov/pubmed/34815681
http://dx.doi.org/10.2147/DMSO.S338254
work_keys_str_mv AT alabsiboshra plasmalipocalin2andadiponectinareaffectedbyobesityratherthantype2diabetesmellitusperse
AT alhaborimolham plasmalipocalin2andadiponectinareaffectedbyobesityratherthantype2diabetesmellitusperse
AT saifaliriyadh plasmalipocalin2andadiponectinareaffectedbyobesityratherthantype2diabetesmellitusperse